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Hyun Ju Lee, MD,* Choon-Taek Lee, MD, PhD,† Jong Seok Lee, MD, PhD,†
Sanghoon Jheon, MD, PhD,‡ and Jin-Haeng Chung, MD, PhD*
Background: The use of a standard immunohistochemistry (IHC)
assay to detect the anaplastic lymphoma kinase (ALK) protein in
lung cancer is challenging. There are no universally accepted,
evidence-based guidelines on identifying patients with ALK-rear-
ranged lung cancer using IHC.
Methods: We retrospectively reviewed 465 resected specimens of
non-small cell lung cancer using a tissue microarray as a test set.
ALK protein expression using IHC with 5A4 monoclonal antibody
(Novocastra) and ALK gene rearrangement using fluorescence in situ
hybridization (FISH) with dual-color break-apart probes (Abbott
molecular) were examined. Immunoreactivity was scored as 0, 1, 2,
or 3, and the results were compared with the FISH results. A
diagnostic algorithm was derived from the correlation of the IHC
and FISH results and applied to an additional 187 adenocarcinoma
samples used as a validation set.
Results: In the test set, ALK protein expression was detected in 40
patients (40/465, 8.6%), consisting of IHC scores of 1 (n  14), 2
(n  10), and 3 (n  16), whereas 19 patients (19/453, 4.2%) were
FISH-positive. All the FISH-positive patients were assigned IHC
scores of 2 or 3. All the patients with ALK IHC scores of 3 were
FISH-positive, those with scores of 0 or 1 were FISH-negative, and
those with scores of 2 were FISH variable. In the validation set,
ALK protein expression was detected in 14 patients (scores of 1, n
2; scores of 2, n  6; and scores of 3, n  6), of which nine patients
(9/187, 4.8%) were FISH-positive. All the patients with IHC scores
of 0 or 1 were FISH-negative, and those with scores of 3 were FISH-
positive. Among the patients with IHC scores of 2, three (3/6, 50%)
were FISH-positive.
Conclusions: The sensitivity and specificity of IHC was 100% and
95.8%, respectively. These data supported an IHC scoring algorithm
in which ALK IHC scores of 0, 1, or 3 were highly compatible with
FISH results, and IHC scores of 2 were variable. Based on these
findings, the IHC assay using the 5A4 antibody reliably detected
non-small cell lung cancer with ALK rearrangement and may be
useful as a screening method to identify these tumors.
Key Words: EML4-ALK, Non-small cell lung cancer, Immunohis-
tochemistry, Fluorescence in situ hybridization.
(J Thorac Oncol. 2011;6: 466–472)
Lung cancer is the leading cause of cancer-related deaths inthe world, despite improvements in detection methods and
treatments.1,2 Recent studies on personalized treatment by
selecting patients who are likely to respond to a particular
therapeutic agent may allow improved treatment efficacy.3–5
Most notably, a subset of patients with non-small cell lung
cancer (NSCLC) with activating mutations in the epidermal
growth factor receptor (EGFR) gene show dramatic re-
sponses to drugs that inhibit EGFR kinase activity, resulting
in prolonged survival.3,5 It is expected that the use of targeted
therapies for NSCLC in biomarker-selected patients will
increase.
Recently, activation of the anaplastic lymphoma kinase
(ALK) gene in lung cancer by fusion to echinoderm micro-
tubule-associated protein-like 4 or other gene partners was
reported.6 ALK is a receptor tyrosine kinase described in
anaplastic large cell lymphoma with t(2;5)(p23;q35) resulting
in a nucleophosmin-ALK fusion protein. The ALK-signaling
pathway includes several biologically important pathways
involving cell proliferation, differentiation, and antiapopto-
sis.4 In NSCLC, the ALK gene is most commonly fused with
echinoderm microtubule-associated protein-like 4, and the
frequency of the fusion gene is approximately 3 to 6.7%.4,7–10
A novel ALK tyrosine kinase inhibitor named crizotinib
(PF-02341066) is currently in phase II and phase III clinical
trials for advanced NSCLC with ALK rearrangement, and
early studies have demonstrated dramatic clinical responses
in patients with ALK-rearranged NSCLC assessed using flu-
orescence in situ hybridization (FISH).11,12
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The introduction of an effective and widely applicable
screening method using immunohistochemistry (IHC) to de-
tect NSCLC with ALK rearrangement is vital because ALK
rearrangement status has been determined in few patients at
the time of excision of the primary lesion. Nonetheless, ALK
IHC testing in lung cancer remains challenging because of the
relatively low level of ALK transcription, few data about the
sensitivity or specificity of the test, and the absence of a
universally accepted and evidence-based IHC scoring algo-
rithm to predict ALK rearrangement using FISH.4,7–10,13
FISH is standard method to detect ALK rearrangement,
but it is not readily available to as a routine method in the
pathology practice. As IHC is a commonly used technique in
the pathology laboratories, several strategies have been tried
to improve the accuracy of the ALK IHC assays in lung
cancer including amplification of the signal with a tyramide
cascade,14 intercalation of an antibody-enhanced polymer,15
or development of novel antibodies.13
In this study, we semiquantitatively evaluated ALK
rearrangement using IHC and correlated the results with
results obtained using FISH. The aim of this study was to
acquire the baseline ALK rearrangement status of Korean
patients with NSCLC and to determine a sensitive screening
method using IHC to predict FISH results.
PATIENTS AND METHODS
Patients and Samples
This study included 465 consecutive patients with
NSCLC who underwent surgical resection at the Seoul Na-
tional University Bundang Hospital in Korea from May 2003
to May 2008 as a test set using tissue microarray (TMA). The
cohort consisted of 269 cases of adenocarcinoma (ADC), 169
cases of squamous cell carcinoma, 10 cases of adenosqua-
mous carcinoma, five cases of pleomorphic carcinoma, two
cases of large cell carcinoma, eight cases of large cell neu-
roendocrine carcinoma, one case of carcinosarcoma, and one
case of lymphoepithelioma-like carcinoma. The mean age of
the 465 patients was 63.8 years and ranged from 21 to 84. To
validate our results, we examined whole sections of surgi-
cally resected or biopsied samples from 187 patients with
ADC at the Seoul National University Bundang Hospital in
Korea from September 2009 to May 2010 using IHC. This
study was approved by the institutional review boards at the
Seoul National University Bundang Hospital.
Construction of the TMA
One representative core tissue (2 mm in diameter) was
taken from a paraffin block of each case and arranged in new
TMA blocks using a trephine apparatus (Superbiochips Lab-
oratories, Seoul, Korea), as described previously.16 Two se-
rial sections were cut and examined using IHC and FISH.
Immunohistochemistry
Formalin-fixed and paraffin-embedded (FFPE) tissues
were sectioned at a thickness of 4 m and stained using a
Ventana automated immunostainer (Ventana Medical Sys-
tems, Tucson, AZ) according to the manufacturer’s protocol.
Briefly, the slides were dried at 60°C for 1 hour and depar-
affinized using EZ Prep (Ventana Medical Systems) at 75°C
for 4 minutes. The cells were conditioned (heat pretreatment)
using a CC1 solution containing Tris/borate/ethylenediami-
netetraacetic acid at 100°C for 20 minutes. The antibody for
ALK (mouse monoclonal, clone 5A4, Novocastra, New-
castle, United Kingdom) was diluted to 1:30, treated, and
incubated at 42°C for 2 hours. Signals were detected using an
i-view detection kit (Ventana Medical Systems) based on the
labeled streptavidin-biotin method. The steps used with the
kit included treatment with an inhibitor (1% H2O2, 4 min-
utes), biotinylated immunoglobulin (8 minutes), streptavidin-
horseradish peroxidase (8 minutes), diaminobenzidine (chro-
mogen  substrate) (8 minutes), and copper (4 minutes) at
37°C. Counterstaining was performed with Mayer’s hema-
toxylin (ScyTek, Logan, UT) for 2 minutes at room temper-
ature.
Fluorescence In Situ Hybridization
FISH was performed on FFPE tumor tissues using a
break-apart probe specific to the ALK locus (Vysis LSI ALK
dual-color, break-apart rearrangement probe; Abbott Molec-
ular, Abbott Park, IL) according to the manufacturer’s in-
structions. FISH-positive cases were defined as those present-
ing more than 15% split signals or an isolated red signal (IRS)
in tumor cells, as described previously.17,18 Briefly, 3-m-
thick sections from FFPE tissue blocks were deparaffinized,
dehydrated, immersed in 0.2 N HCl, and washed. The sec-
tions were immersed in 0.01 M citrate buffer, boiled in a
microwave for 5 minutes, treated with pretreatment reagent
(Abbott Molecular) at 80°C for 30 minutes, and reacted with
protease mixed with a protease buffer. Dual-probe hybridiza-
tion was performed using the LSI ALK dual-color probe,
which hybridizes to the 2p23 band with SpectrumOrange
(red) and SpectrumGreen on either side of the ALK gene
breakpoint (Abbott Molecular). After applying the probe
mixture, they were treated with protease, incubated in a
humidified atmosphere with HybriteTM (Abbott Molecular)
at 75°C for 5 minutes to denature the probe and target the
DNA, and incubated at 37°C for 16 hours to allow hybrid-
ization. They were then immersed in 0.3% NP-40 (Abbott
Molecular)/2 saline sodium citrate for washing. For the
nuclei counterstaining, 4,6-diamidino-2-phenylindole II and
an antifade compound (p-phenylenediamine) were applied.
Signals for each probe were evaluated under a microscope
equipped with a triple-pass filter (diamidino-2-phenylindole/
Green/Orange; Abbott Molecular) and an oil immersion ob-
jective lens. FISH tests were performed without knowledge
of the IHC results for ALK.
EGFR and K-ras Mutation Study
All the cases that were determined to be ALK FISH-
positive and some of the cases that were determined to be
ALK FISH-negative were analyzed for EGFR mutations at
exons 18 to 21 and K-ras mutations at codons 12, 13, and 61
using the polymerase chain reaction and a direct DNA se-
quencing method, as described previously.19 EGFR mutations
in some patients included in this study had been identified
previously.19
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Statistical Analysis
SPSS version 12.0 (Systat, Chicago, IL) was used for
the statistical analysis, which included Pearson’s 2 test,
Pearson’s R test, and Fisher’s exact test. Statistical signifi-
cance was defined as p  0.05.
RESULTS
ALK Immunoreactivity by IHC in the Test Set
ALK protein expression was observed in tumor cells
with a predominantly cytoplasmic staining pattern. Nonneo-
plastic bronchial epithelium, alveolar type I and type II
pneumocytes, mesenchymal tissue, and inflammatory cells in
the adjacent lung tissue were negative for ALK. A few
alveolar macrophages adjacent to positively stained tumor
cells showed faint granular cytoplasmic staining. Neverthe-
less, alveolar macrophages were not stained in the NSCLC
cases in the absence of ALK protein expression. The mucin-
rich cytoplasm of the tumor cells showed faint, granular
immunoreactivity for ALK. The expression of ALK was
assessed semiquantitatively by three pathologists (J.H.P.,
G.C., and J.-H.C.) without knowledge of the results obtained
using FISH or the clinicopathologic information. Semiquan-
titative assessment was performed by estimating the staining
intensity and the percentage of tumor cells using positive
cytoplasmic staining. Each cell was first scored as 0, 1, 2, or
3, which corresponded to negative, weak, moderate, and
strong staining intensities, respectively. Next, we evaluated
the percentage of positively stained cells. Increases in the
staining intensity were associated with increases in the num-
ber of positively stained cells observed: a staining intensity of
1 resulted in an average of 14.7% positively stained cells, a
staining intensity of 2 resulted in 58.2% positively stained
cells, and a staining intensity of 3 resulted in 97.3% positively
stained cells. ALK IHC scores were assigned as follows: 0,
no stained cells; 1, faint or weak staining intensity with more
than 5% tumor cells or any staining intensity with 5%
tumor cells; 2, moderate staining intensity with more than 5%
tumor cells; and 3, strong staining intensity with more than
5% tumor cells.
ALK protein expression was detected in 8.6% (40/465)
of the NSCLC cases, which included scores of 0 (n  425),
1 (n  14), 2 (n  10), and 3 (n  16) (Figures 1A–D). The
interobserver agreement between pathologists was excellent
( value, 0.92).
ALK Rearrangement Assessed by FISH in the
Test Set
ALK rearrangement was assessed using FISH in 453
patients (97.1%), and ALK rearrangement was identified in 19
patients (4.2%). The majority of the ALK FISH-negative
cases showed two fusion signals or close proximity of the red
FIGURE 1. Immunohistochemical staining pat-
terns and fluorescence in situ hybridization-posi-
tive patterns using an LSI anaplastic lymphoma
kinase (ALK) dual-color break-apart probe for ALK.
A, 0 or negative, no staining; (B) 1, weak and
faint cytoplasmic staining intensity and 70% posi-
tively stained cells; (C) 2, moderate cytoplasmic
staining intensity and 100% positively stained
cells; (D) 3, strong, dark brown cytoplasmic
staining intensity and 100% positively stained
cells (all 400); (E) two distinct red and green
(break apart) signals and one intact fusion signal;
and (F) an isolated red signal (IRS) and one intact
fusion signal.
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and green signals. Nevertheless, a few cells demonstrated an
isolated green signal (IGS) with loss of the corresponding red
signal. As the tyrosine kinase domain resides in the 5 end
probe of ALK (the green signal), an IGS was considered to
correspond to no ALK rearrangement. The clinical signifi-
cance of IGS is unknown.
The ALK FISH-positive NSCLC cases showed two
major patterns using the LSI ALK dual-color break-apart
probe as follows: (1) the break-apart (split) pattern was
observed in 73.7% of cases (14/19) (Figure 1E) and (2) IRS
pattern: the isolated (single) red signal was predominant in
26.3% of cases (5/19) (Figure 1F). The interobserver agree-
ment between pathologists was excellent ( value, 0.94).
Regarding discordant cases (usually IHC 2 cases), three
pathologists repeatedly examined, scored the cases, and dis-
cussed together, which led to the consensus scoring.
Correlation between ALK Protein Expression as
Determined by IHC and ALK Rearrangement as
Determined by FISH
To determine the best criteria for IHC assessment to
predict gene rearrangements, we compared the ALK results
using IHC and FISH in the test set (Table 1). The average
percentage of cells positively stained using IHC was higher in
the FISH-positive tumors than in the FISH-negative tumors
(92.4% versus 19.3%). All the cases with IHC scores of 3
were FISH-positive, and all the cases with IHC scores of 0 or
1 were FISH-negative. For cases with scores of 2, 30% (3/10)
were FISH-positive and 70% (7/10) were FISH-negative. The
overall sensitivity of IHC was 100%, and the specificity was
95.2% in the test set. There were 21 false-positive cases (14
cases of score 1 and seven cases of score 2) and no false-
negative cases using IHC. Assuming that ALK IHC scores of
0 and 1 were ALK rearrangement-negative, an ALK IHC
score of 3 was ALK rearrangement-positive, and an ALK IHC
score of 2 was equivocal, the results of the ALK IHC assay
using the tiered scoring method and FISH were strongly
correlated (p  0.001). After excluding cases with ALK IHC
scores of 2 (equivocal), the ALK IHC scores (0 and 1
versus 3) and ALK FISH (negative versus positive) were com-
pletely correlated. These results indicate that an ALK IHC score
of 3 could strongly predict FISH-positivity and an IHC score of
0 or 1 could predict FISH-negativity. A diagnostic algorithm
was derived from these results (Figure 2).
Validation of the IHC Interpretation Criteria to
Detect ALK FISH-Positive NSCLC
As a validation set, we examined surgically resected or
biopsied specimens from 187 patients with ADC and applied the
IHC interpretation algorithm. Among these specimens, 14 were
positively stained for ALK, including two cases of ALK IHC
score of 1, six with a score of 2, and six with a score of 3
(Table 2). The FISH results were as follows: all the patients with
an IHC score of 0 or 1 were FISH-negative, and six of the
patients with an IHC score of 3 were FISH-positive. The cases
with scores of 2 were 50% (3/6) FISH-positive (Table 2). Nine
FISH-positive cases included seven break-apart (split) patterns
and two IRS patterns. There were five false positives (two cases
with a score of 1 and three cases with a score of 2) and no
false-negative cases. The diagnostic algorithm derived from the
test set was effective in the validation set.
Table 3 lists the correlation of the results usingALK IHCand
FISH in all 640 cases, including the test and validation sets.
Analysis of Clinicopathologic Characteristics of
Lung Cancer with ALK Rearrangement
Clinicopathologic factors associated with ALK
rearrangement in the surgically resected NSCLC
(test set)
Nineteen ALK FISH-positive patients (4.2%), com-
posed of 11 men and eight women, presented ADC histology
(except for one case of adenosquamous carcinoma). Neither








FIGURE 2. Diagnostic algorithm using anaplastic lym-
phoma kinase (ALK) immunohistochemistry and fluorescence
in situ hybridization in non-small cell lung cancer.





0 0 413 (91.2) 413 (91.2)
1 0 14 (3.1) 14 (3.1)
2 3 (0.7) 7 (1.5) 10 (2.2)
3 16 (3.5) 0 16 (3.5)
Total 19 (4.2) 434 (95.8) 453 (100)
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; ALK, ana-
plastic lymphoma kinase.





0 0 173 (92.5) 173 (92.5)
1 0 2 (1.1) 2 (1.1)
2 3 (1.6) 3 (1.6) 6 (3.2)
3 6 (3.2) 0 6 (3.2)
Total 9 (4.8) 178 (95.2) 187 (100)
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; ALK, ana-
plastic lymphoma kinase.
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rangement. The patients with ALK-rearranged NSCLC in the
surgically resected group exhibited ADC histology (p 
0.001) and an absence of EGFR or K-ras mutations (p 
0.001). Nevertheless, sex, age, smoking habit, tumor size, and
pathologic stage were not significantly different between
ALK-positive and -negative groups (Table 4).
Clinicopathologic factors associated with ALK
rearrangement in the consecutive ADCs
(validation set)
ALK rearrangement was identified in 9 of 187 patients
(4.8%) having ADC between September 2009 and May 2010
(Table 5). The mean age of these ALK FISH-positive patients
was 48.7 years (range: 28–71). In contrast to the test set, ALK
FISH-positive patients were younger than ALK FISH-negative
patients (mean 62.0 years; range: 27–91) in the ADC-only
validation set (p  0.014). There were six women and three
men constituting the ALK FISH-positive patients. Neither
EGFR nor K-ras mutations were identified. In addition to the
younger age, the patients with ALK rearrangement demon-
strated an absence of EGFR or K-ras mutations (p  0.001).
Nevertheless, sex, smoking habit, tumor size, and pathologic
stage were not significantly different between ALK FISH-
positive and ALK FISH-negative groups. Even though non-
smokers tended to exhibit ALK rearrangement more fre-
quently (6/104, 5.8%) than smokers (3/83, 3.6%), this was
not statistically significant (Table 5, p  0.733).





0 0 586 (91.6) 586 (91.6)
1 0 16 (2.5) 16 (2.5)
2 6 (0.9) 10 (1.6) 16 (2.5)
3 22 (3.4) 0 22 (3.4)
Total 28 (4.4) 612 (95.6) 640 (100)
IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; ALK, ana-
plastic lymphoma kinase.
TABLE 4. The Relationship between ALK FISH and




Total 453 (100) 19 (4.2) 434 (95.8)
Sex
Male 309 (68.2) 11 (57.9) 298 (68.7) 0.324
Female 144 (31.8) 8 (42.1) 136 (31.3)
Age (yr)
65 230 (50.8) 6 (31.6) 224 (51.6) 0.103
65 223 (49.2) 13 (68.4) 210 (48.4)
Smoking habit
Never 171 (37.7) 10 (52.6) 161 (37.1) 0.226
Smoker 282 (62.3) 9 (47.4) 273 (62.9)
Tumor size (cm)
3 210 (46.4) 6 (31.6) 204 (47.0) 0.242
3 243 (53.6) 13 (68.4) 230 (53.0)
Histology
ADC 263 (58.1) 18 (94.7) 245 (56.5) 0.001a
SCC 163 (36.0) 0 163 (37.5)
Others 27 (5.9) 1 (5.3) 26 (6.0)
EGFR
Mutation () 41 (9.1) 0 41 (9.4) 0.001a
Mutation () 49 (10.8) 19 (100) 30 (6.9)
NA 363 (80.1) 0 363 (83.6)
K-ras
Mutation () 7 (1.5) 0 7 (1.6) 0.001a
Mutation () 57 (12.6) 19 (100) 38 (8.8)
NA 389 (85.9) 0 389 (89.6)
p stage
I 198 (43.7) 8 (42.1) 190 (43.8) 1.000
II–IV 255 (56.3) 11 (57.9) 244 (56.2)
a p  0.05.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; FISH, fluorescence in situ
hybridization; NA, not applicable; p stage, pathologic stage; ALK, anaplastic lymphoma
kinase; EGFR, epidermal growth factor receptor.
TABLE 5. The Relationship between ALK FISH and




Total 187 (100) 9 (4.8) 178 (95.2)
Sex
Male 105 (56.1) 3 (33.3) 102 (57.3) 0.184
Female 82 (43.9) 6 (66.7) 76 (42.7)
Age (yr)
65 71 (38.0) 0 71 (39.9) 0.014a
65 116 (62.0) 9 (100) 107 (60.1)
Smoking habit
Never 104 (55.6) 6 (66.7) 98 (55.1) 0.733
Smoker 83 (44.4) 3 (33.3) 80 (44.9)
Tumor size (cm)
3 77 (41.2) 5 (55.6) 72 (40.4) 0.491
3 110 (58.8) 4 (44.4) 106 (59.6)
Histology
ADC 187 (100) 9 (100) 178 (100)
SCC 0 0 0
Others 0 0 0
EGFR
Mutation () 62 (33.2) 0 62 (34.8) 0.001a
Mutation () 56 (29.9) 9 (100) 47 (26.4)
NA 69 (36.9) 0 69 (38.8)
K-ras
Mutation () 6 (3.2) 0 6 (3.4) 0.001a
Mutation () 54 (28.9) 9 (100) 45 (25.3)
NA 127 (67.9) 0 127 (71.3)
p stage
I 64 (34.2) 3 (33.3) 61 (34.3) 1.000
II–IV 123 (65.8) 6 (66.7) 117 (65.7)
a p  0.05.
ALK, anaplastic lymphoma kinase; ADC, adenocarcinoma; SCC, squamous cell
carcinoma; FISH, fluorescence in situ hybridization; NA, not applicable; p stage,
pathologic stage; EGFR, epidermal growth factor receptor.
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The clinicopathologic features of all 28 ALK FISH-
positive patients are summarized in Table 6.
DISCUSSION
FISH analysis using the ALK break-apart probe was the
standard test for enrollment in a clinical trial with crizotinib.12
Because the incidence of ALK rearrangement in NSCLC is
relatively low and the ALK rearrangement status is infre-
quently determined at the time of excision of primary lesions,
it is difficult to use FISH on all the biopsied or archived
NSCLC samples. Therefore, the development of a screening
method to identify ALK-rearranged tumors is imperative, and
the diagnostic test needs to be applicable to archived, forma-
lin-fixed tissues that have been removed up to several years
earlier. Because IHC is readily available in pathology labo-
ratories, it is important to optimize the condition of ALK IHC
assay as a screening method and to establish an interpretation
guideline.
In this study, we observed a good correlation between
results obtained using IHC and FISH in a large-scale, single-
institution study using a semiquantitative IHC scoring assess-
ment. We also presented a diagnostic algorithm to screen for
NSCLC with ALK rearrangements using IHC (Figure 2).
In the test set, good correlations were observed between
cases assigned ALK IHC scores of 3 and FISH-positivity, as
well as ALK IHC scores of 0 and 1 and FISH-negativity.
Nevertheless, cases assigned ALK IHC scores of 2 showed
variable FISH results. The proposed diagnostic algorithm was
also effective in the validation set, which included 187
consecutive ADCs. Because there were no false-negative
ALK IHC results using the 5A4 antibody (Novocastra) in 640
patients with NSCLC (453 in the test set and 187 in the
validation set), ALK IHC would be a suitable method to
screen for ALK rearrangement.
For FISH, we used break-apart probes specific to the 5
and 3 ends of ALK (Abbott Molecular) for identifying ALK
rearrangement. Although this method is sensitive for detect-
ing the breakage of the ALK, it does not identify the 5 fusion
partner or the exact breakpoint. To overcome these problems,
several new methods including novel break-apart probes
designed for the detection of both ALK and fusion partner
genes are being explored or developed.20
In this study, there were two major patterns of ALK
rearrangement, i.e., break apart (75%, 21/28) and IRS (25%,
7/28). The IRS pattern appears to be unique in NSCLC,
unlike anaplastic large cell lymphoma. Although some re-
ports have described this pattern previously in NSCLC, its
relatively high frequency and correlations of immunoreactiv-
ity have not been reported.18,20 Significant differences in
clinicopathologic factors were not identified between the two
patterns of ALK rearrangement (data not shown). Although
the mechanism of the IRS pattern is not yet clear, it might be
associated with various breakpoints of the ALK gene. On the
other hand, a few patients showed an IGS, where the tyrosine
kinase domain resides. Loss of the red-labeled probe might be
associated with the loss of the probe on 2p outside the area
encoding for the ALK kinase domain. The clinical signifi-
cances of IRS and IGS need to be clarified. In this study, it
was impossible to assess the specimens using FISH in 12
cases of TMA due to signal loss or background autofluores-
cence. Inappropriate fixation in formalin before tissue pro-
cessing may result in background autofluorescence or more
aggressive tissue permeabilization, possibly leading to loss of
signal and poor tissue preservation. The standardization of all
preanalytical variables, including tissue handling, fixation,
and processing, is important when using FISH.21
Patients exhibiting ALK rearrangement in the test set
demonstrated ADC histology and the absence of EGFR or
K-ras mutations. Sex, age, smoking habit, tumor size, and
pathologic stage were not significant factors in the surgically
resected NSCLC specimens. When the test and validation
sets were integrated, the cohort of screened patients harboring
ALK rearrangement was enriched in young patients, patients
with ADC histology, and the absence of EGFR or K-ras
mutations (Table 6). Sex, smoking habit, pathologic stage,
and tumor size were not associated with ALK-rearranged
NSCLC. These features were not fully consistent with previ-
ous reports in which the patients most likely to harbor
TABLE 6. The Relationship between ALK FISH and




Total 640 (100) 28 (4.4) 612 (95.6)
Sex
Male 414 (64.7) 14 (50.0) 400 (65.4) 0.108
Female 226 (35.3) 14 (50.0) 212 (34.6)
Age (yr)
65 301 (47.0) 6 (21.4) 295 (48.2) 0.006a
65 339 (53.0) 22 (78.6) 317 (51.8)
Smoking habit
Never 275 (43.0) 16 (57.1) 259 (42.3) 0.171
Smoker 365 (57.0) 12 (42.9) 353 (57.7)
Tumor size (cm)
3 287 (44.8) 11 (39.3) 276 (45.1) 0.568
3 353 (55.2) 17 (60.7) 336 (54.9)
Histology
ADC 450 (70.3) 27 (96.4) 423 (69.1) 0.001a
SCC 163 (25.5) 0 163 (26.6)
Others 27 (4.2) 1 (3.8) 26 (4.2)
EGFR
Mutation () 103 (16.1) 0 103 (16.8) 0.001a
Mutation () 105 (16.4) 28 (100) 77 (12.6)
NA 432 (67.5) 0 432 (70.6)
K-ras
Mutation () 13 (2.0) 0 13 (2.1) 0.001a
Mutation () 111 (17.3) 28 (100) 83 (13.6)
NA 516 (80.6) 0 516 (84.3)
p stage
I 262 (40.9) 11 (39.3) 251 (41.0) 1.000
II–IV 378 (59.1) 17 (60.7) 361 (59.0)
a p  0.05.
ALK, anaplastic lymphoma kinase; ADC, adenocarcinoma; SCC, squamous cell
carcinoma; FISH, fluorescence in situ hybridization; NA, not applicable; p stage,
pathologic stage; EGFR, epidermal growth factor receptor.
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ALK-rearranged NSCLC were men, young, never/light smok-
ers with ADC histology.17 In our study, sex and smoking
history were not significant clinical features, whereas young
age was significantly associated with ALK rearrangement
only in the consecutive ADC group (the validation set). These
trends might be due to the low incidence of ALK rearrange-
ment, which might affect the statistics by infrequently includ-
ing patients with ALK-rearranged NSCLC. Therefore, a
large-scale meta-analysis would be needed to delineate the
specific features corresponding to ALK-rearranged NSCLC.
In summary, we present a diagnostic algorithm using
ALK IHC to predict ALK gene rearrangement. ALK FISH
results were completely predicted in patients with IHC scores
of 0, 1, and 3, whereas patients with IHC scores of 2
demonstrated variable FISH results. This algorithmic ap-
proach might be useful as a screening method for ALK gene
rearrangement. In addition, patients with ALK rearrangement
in the test set demonstrated ADC histology and an absence of
EGFR or K-ras mutations. Nevertheless, sex, age, and smok-
ing status were not solid variables associated with ALK-
rearranged NSCLC. Our results suggest that more careful
interpretation of the clinicopathologic characteristics of ALK-
rearranged NSCLC is necessary.
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